You are using an outdated browser. Please upgrade your browser to improve your experience and security.

What is VYXEOS?

VYXEOS (vix-e-ose) is an intravenous (IV) chemotherapy used for the treatment of adults and pediatric patients 1 year and older with certain types of newly-diagnosed secondary acute myeloid leukemia (sAML): therapy-related AML (t-AML) or AML with myelodysplasia-related changes (AML-MRC).

How is VYXEOS different?

VYXEOS is an advancement from traditional chemotherapy for adults with certain types of newly-diagnosed sAML. It is the only treatment for these types of AML that combines 2 currently used, effective chemotherapies into tiny, bubble-like carriers called liposomes, which carry the drugs to the bone marrow. The liposomes are taken up by leukemia cells (blasts) to a greater extent than by normal cells. Once inside, the liposomes release the drugs to help kill the blasts. This type of technology, combining 2 drugs within a liposome, is the first of its kind in AML treatment.

IV Bag icon

Chemotherapy solutions can be various colors. The VYXEOS solution is purple.

WHAT IS VYXEOS?

VYXEOS is an intravenous (IV) chemotherapy used for the treatment of certain types of newly-diagnosed acute myeloid leukemia (AML) in adults and pediatric patients 1 year and older, including patients whose AML is related to previously received chemotherapy or radiation therapy (also called therapy-related AML, t-AML) and AML in patients who previously had certain types of blood disorders (also called AML with myelodysplasia-related changes, AML-MRC).

IMPORTANT SAFETY INFORMATION

Important Safety Information

VYXEOS has different dosage recommendations from other medications that contain daunorubicin and/or cytarabine. Do not substitute VYXEOS for other daunorubicin and/or cytarabine-containing products.